» Articles » PMID: 25506088

Assessing the Heterogeneity of Treatment Effects Via Potential Outcomes of Individual Patients

Overview
Specialty Public Health
Date 2014 Dec 16
PMID 25506088
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

There is growing interest in understanding the heterogeneity of treatment effects (HTE), which has important implications in treatment evaluation and selection. The standard approach to assessing HTE (i.e. subgroup analyses based on known effect modifiers) is informative about the heterogeneity between subpopulations but not within. It is arguably more informative to assess HTE in terms of individual treatment effects, which can be defined by using potential outcomes. However, estimation of HTE based on potential outcomes is challenged by the lack of complete identifiability. The paper proposes methods to deal with the identifiability problem by using relevant information in baseline covariates and repeated measurements. If a set of covariates is sufficient for explaining the dependence between potential outcomes, the joint distribution of potential outcomes and hence all measures of HTE will then be identified under a conditional independence assumption. Possible violations of this assumption can be addressed by including a random effect to account for residual dependence or by specifying the conditional dependence structure directly. The methods proposed are shown to reduce effectively the uncertainty about HTE in a trial of human immunodeficiency virus.

Citing Articles

Adaptive Enrichment Designs in Clinical Trials.

Thall P Annu Rev Stat Appl. 2022; 8(1):393-411.

PMID: 36212769 PMC: 9544313. DOI: 10.1146/annurev-statistics-040720-032818.


A likely responder approach for the analysis of randomized controlled trials.

Laska E, Siegel C, Lin Z Contemp Clin Trials. 2022; 114:106688.

PMID: 35085831 PMC: 8934276. DOI: 10.1016/j.cct.2022.106688.


Applying methods for personalized medicine to the treatment of alcohol use disorder.

Kuhlemeier A, Desai Y, Tonigan A, Witkiewitz K, Jaki T, Hsiao Y J Consult Clin Psychol. 2021; 89(4):288-300.

PMID: 34014691 PMC: 8284918. DOI: 10.1037/ccp0000634.


Capturing heterogeneity in repeated measures data by fusion penalty.

Liu L, Gordon M, Miller J, Kass M, Lin L, Ma S Stat Med. 2021; 40(8):1901-1916.

PMID: 33517583 PMC: 8366591. DOI: 10.1002/sim.8878.


Constructing a confidence interval for the fraction who benefit from treatment, using randomized trial data.

Huang E, Fang E, Hanley D, Rosenblum M Biometrics. 2019; 75(4):1228-1239.

PMID: 31206586 PMC: 6895397. DOI: 10.1111/biom.13101.


References
1.
Poulson R, Gadbury G, Allison D . Treatment Heterogeneity and Individual Qualitative Interaction. Am Stat. 2012; 66(1):16-24. PMC: 3507541. DOI: 10.1080/00031305.2012.671724. View

2.
Huang Y, B Gilbert P, Janes H . Assessing treatment-selection markers using a potential outcomes framework. Biometrics. 2012; 68(3):687-96. PMC: 3417090. DOI: 10.1111/j.1541-0420.2011.01722.x. View

3.
Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman A, Lampiris H . Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008; 359(14):1442-55. DOI: 10.1056/NEJMoa0803154. View

4.
Gulick R, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A . Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008; 359(14):1429-41. PMC: 3078519. DOI: 10.1056/NEJMoa0803152. View

5.
Gadbury G, Iyer H . Unit-treatment interaction and its practical consequences. Biometrics. 2000; 56(3):882-5. DOI: 10.1111/j.0006-341x.2000.00882.x. View